<DOC>
	<DOCNO>NCT01609478</DOCNO>
	<brief_summary>To provide efficacy , safety pharmacokinetics indacaterol acetate patient persistent asthma support dose selection indacaterol fix dose combination QMF149 .</brief_summary>
	<brief_title>Efficacy , Safety Pharmacokinetics Indacaterol Acetate Patients With Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Patients persistent asthma , diagnose accord GINA 2010 guideline additionally meet follow criterion : Patients receive ICS treatment stable regimen ≥ 4 week Patients prebronchodilator FEV1 value ≥ 40 % ≤ 80 % predict normal value Patients demonstrate increase &gt; = 12 % 200 mL FEV1 ACQ5 score ≥ 1.5 Patients current smoker smoke history great 10 pack year ( defined number pack 20 cigarette smoke per day multiply number year patient smoke ) . Patients chronic lung disease , include COPD , pulmonary tuberculosis , bronchiectasis , sarcoidosis , interstitial lung disease cystic fibrosis . Patients chronic condition affect respiratory tract ( e.g. , chronic sinusitis ) opinion investigator may interfere study evaluation optimal participation study . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>asthma</keyword>
</DOC>